BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28085016)

  • 1. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
    Waight JD; Gombos RB; Wilson NS
    Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
    Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
    Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
    Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
    Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
    Kumar P; Bhattacharya P; Prabhakar BS
    J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
    Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
    Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
    Bulliard Y; Jolicoeur R; Zhang J; Dranoff G; Wilson NS; Brogdon JL
    Immunol Cell Biol; 2014 Jul; 92(6):475-80. PubMed ID: 24732076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
    Croft M
    Nat Rev Immunol; 2003 Aug; 3(8):609-20. PubMed ID: 12974476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
    Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
    Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF/TNFR family members in costimulation of T cell responses.
    Watts TH
    Annu Rev Immunol; 2005; 23():23-68. PubMed ID: 15771565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic potential of 4-1BB (CD137) in cancer.
    Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
    Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
    Moran AE; Kovacsovics-Bankowski M; Weinberg AD
    Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity.
    So T; Lee SW; Croft M
    Int J Hematol; 2006 Jan; 83(1):1-11. PubMed ID: 16443545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TNF-TNFR Family of Co-signal Molecules.
    So T; Ishii N
    Adv Exp Med Biol; 2019; 1189():53-84. PubMed ID: 31758531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for anti-CD137 cancer immunotherapy.
    Makkouk A; Chester C; Kohrt HE
    Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy with agonistic anti-CD137: two sides of a coin.
    Sun Y; Chen JH; Fu Y
    Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
    Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
    J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
    Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
    Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.
    Wasiuk A; Testa J; Weidlick J; Sisson C; Vitale L; Widger J; Crocker A; Thomas LJ; Goldstein J; Marsh HC; Keler T; He LZ
    J Immunol; 2017 Dec; 199(12):4110-4123. PubMed ID: 29109120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.